Viridian Therapeutics, Inc.\DE (VRDN)
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
Address
221 CRESCENT STREET
WALTHAM, MA 02453
Founded
2006
Number of Employees
96
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)